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Due to the emergence of multi-drug resistant bacteria, and the evident limitation in thera-
peutic options, alternatives to combat bacterial infections have been sought. One of these is
phage therapy, which is the use of bacterial viruses to kill pathogenic bacteria responsible
for  the infection. These viruses called bacteriophages are very abundant organisms in the
world and are harmless to humans. There are several advantages in using phage therapy,
especially against multi-drug resistant pathogens, which tend to be dominated by individ-
ual strains. The advantages include fewer collateral effects such as lower disturbance of gut
microbiota and less antimicrobials consumption, which itself leads to reducing antibiotic
resistance rates. Unfortunately, few clinical studies have been initiated in Brazil and this area
is  little explored in our country. This manuscript describes clinical evidence of successful
phage  utilization on pathogens considered a threat in Brazil, highlighting the benefits of a
possible phage utilization as an important tool to combat antimicrobial resistance in ourcountry.
©  2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espan˜a, S.L.U. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/ntimicrobial resistance in Brazil has been a frequent topic
f discussion over the last few years. Currently, the country
s experiencing a scenario where resistance to antimicrobial
gents is emerging so quickly, that many  people are claim-
ng that the antibiotic era is coming to an end. Although new
ombinations of -lactams and -lactams inhibitors are beingPlease cite this article in press as: Martins WM, et al. Clinical utilization
resistance in Brazil. Braz J Infect Dis. 2020. https://doi.org/10.1016/j.bjid.20
ntroduced into clinical use, multi-drug and pan-drug resis-
ant isolates have been characterized around the world calling
nto question how much one should be held hostage to the
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sole use of antimicrobial agents in treating infections. Since
there are numerous review manuscripts addressing phage
therapy, the purpose of this review is to provide a general
overview about phage utilization, highlighting the Brazilian
scenario with includes the main pathogens or lineages which
need concentrated efforts and the Brazilian investigations
conducted on this topic. In this review, supportive papers
will be indicated to improve the understanding about phage
utilization. of bacteriophages: a new perspective to combat the antimicrobial
20.04.010
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Antimicrobial  resistance  of  Gram-negative
bacilli  as  a  public  health  threat
Antimicrobial resistance has been considered a threat to pub-
lic health in different parts of the world, including middle
and low-income countries such as Brazil.1 The increasing
emergence of multi-drug resistant (MDR) bacteria leads to
poor clinical outcomes for nosocomial patients and increases
the costs associated with hospitalization.2 According to the
Brazilian Health Regulatory Agency (ANVISA) an increase in
carbapenem resistance rates among Gram-negative bacilli has
been observed in the last few years, especially in pathogens
like Acinetobacter spp., Klebsiella pneumoniae, and Pseudomonas
aeruginosa recovered from blood stream infections (BSI) in
2016 (85%, 46.8%, and 42.9%, respectively).3 Although national
reports only focus on cephalosporins, carbapenems, and more
recently polymyxin, studies have demonstrated the presence
of bacterial isolates with multi-drug resistance or extreme
drug resistance (XDR) in different Brazilian regions.4–8
Some antibiotic resistant bacterial clones are endemic
in Brazil, leading to high resistance levels at Brazilian
hospitals. Among them, KPC-2-producing Klebsiella pneumo-
niae (CC258, ST258 and ST11), SPM-1-producing Pseudomonas
aeruginosa (ST277), and carbapenem-hydrolyzing class D
carbapenemase-producing in Acinetobacter baumannnii (ST79)
have gained clinical importance in recent decades.9 For the
last 5–6 years, especially due the emergence of KPC-2 pro-
ducing K. pneumoniae, polymyxin has been largely used to
treat infections caused by these Brazilian endemic clones. On
the other hand, emergence of polymyxin resistance, mainly
among K. pneumoniae and A. baumannii isolates, has been
detected, limiting even more  the therapeutic choices for treat-
ing such infections.10,11
For this reason, researchers from many  nations worldwide
are trying to combat infections caused by MDR pathogens
by using alternative methodologies. Phage therapy is one of
these alternatives to traditional antibiotic therapy and has
been used with great effectiveness in some countries.12
Bacteriophages:  viruses  responsible  for
bacterial  biological  control
Bacteriophages, also called phages, are viruses with the ability
to infect and kill bacteria and are the most abundant organ-
isms on Earth.13 They are found in different environments,
and frequently detected in water, sewage, soil, food, clinical
samples, and others.14 Phages usually infect and kill only a
single bacterial strain or lineage thus not able to infect all types
of bacteria. This specific nature is very positive in the clini-
cal setting, since only pathogenic bacteria would be targeted,
infected and killed, preserving commensal harmless and per-
haps beneficial bacteria.13,14 The bacteriophage infection cycle
can be complex.15 After infecting the bacteria, the phages can
show a lytic or lysogenic cycle. Briefly, in the lytic cycle, thePlease cite this article in press as: Martins WM, et al. Clinical utilization
resistance in Brazil. Braz J Infect Dis. 2020. https://doi.org/10.1016/j.bjid.20
most important cycle for the phage therapy, the virus infects
the bacteria cell, multiplies itself using the cell machinery, and
after a period of time (typically 10–20 min) kills the bacteria
by a lytic phenomenon. After lysis, the countless new viral 0;x x x(x x):xxx–xxx
particles are able to infect new bacterial cells.13,16 In contrast,
in the lysogenic cycle, after infecting the cell viral genetic
material is incorporated on the bacteria genome, staying there
until exogenous stimuli activate its lytic cycle.13,16 It is impor-
tant to notice that for phage therapy, lysogenic phages are
not useful since the necessary type of stimulus is oftentimes
unknown, or requires extreme conditions such as pH, UV light,
or low temperatures.17,18
When bacteriophage was first discovered, their clinical
potential was quickly appreciated. However, initial studies
were fraught with problems and often not well-designed yield-
ing unsatisfactory results.19 This fact combined with the
discovery of antibiotics led to a declining interest in the use
of bacteriophage as a useful therapy in Western medicine. It
is important to notice that although the phage therapy was
not cogitated during some years in several parts of the world,
it was largely used in countries of the former Soviet Union,
as Georgia and Poland.20 However, since the expansion of
antibiotic resistance in Gram negatives in the 90s,19 interest in
phage therapy has increased substantially with many  papers
being published. These new studies were well conducted, and
satisfactory results started to be obtained, stimulating more
and more  interest in clinical bacteriophage utilization.13,14 In
the last years, distinct phages have been characterized with
great potential to combat several infections caused by  MDR
pathogens.
Current  clinical  studies  supporting  the  phages
utilization
As discussed before, phage therapy is based on the use of
lytic phages to kill infectious bacteria whilst leaving human
cells unaffected and with a minor impact on human com-
mensal bacteria.12 Currently, phages are largely used in the
food industry, being considered by FDA as Generally Regarded
as Safe (GRAS).21 One of the biggest achievements in the
phage field was the approval of the first product based on
phage (ListShieldTM) in 2006, being registered for use as an
organic food additive in Europe, Australia and New Zealand.21
Although phage use is frequent by food companies, this
review will emphasize the utilization of these microorganisms
in clinical medicine. Based on that, many  clinical trials are
in progress (Fig. 1) stimulated by the good results obtained
in other fields. Here, we  will summarize some clinical tri-
als against Gram-negative pathogens considered a threat in
Brazil. It is important to notice that this review will focus
on a selection of trials and clinical reports considered by the
authors as relevant to support a future clinical utilization of
phages in Brazil. To better understanding the studies involving
human and animals related to phage utilization in emergent
pathogens, read Mulani et al.22
Acinetobacter  baumannii
Phages against MDR A. baumannii isolates have mostly been
23 of bacteriophages: a new perspective to combat the antimicrobial
20.04.010
described in the last couple of years. Turner et al. performed
a genomic analysis of 37 phages previously deposited in Gen-
Bank and recovered from A. baumannii isolates. So far, none
of the phages described and characterized were recovered
ARTICLE IN PRESSBJID-976; No. of Pages 8
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Fig. 1 – World distribution of clinical trials in humans being conducted or newly  concluded. It is possible to note that just
few countries have invested in clinical trials supporting phage utilization in humans. To have more  information about the
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plinical trials, see the website https://clinicaltrials.gov/.
rom South American samples.23 Despite, a large number of
hages that have been fully characterized, only two clini-
al trials in humans have been reported until now. In the
rst one, a 68-year old diabetic patient was diagnosed with
 chronic pancreatic pseudocyst aggravated by an MDR A.
aumannii infection during his hospitalization. Due to limita-
ion of therapeutic options (susceptible just to minocycline),
 phage cocktail was introduced together with antibiotics.
hage therapy was maintained for more  than four months,
ith a complete recovery of the patient’s condition. During
hage therapy, the bacterial isolate recovered causing the
nfection developed resistance to some phages used in the
ocktail, but in return showed increasing antibiotics suscep-
ibility. The phage resistance was circumvented adding new
hages to the cocktail with activity against MDR  A. baumannii.
o collateral effects due to phage utilization were observed in
he patient.24
The second clinical test involved A. baumannii isolates, in
 77-year old male patient, admitted to a hospital in San
iego, USA with a brain injury. The patient was submit-
ed to craniectomy, followed by infection after the surgical
rocedure. Intraoperative material cultured giving growth
o an MDR  A. baumannii isolate only susceptible to col-
stin (some cultures showed A. baumannii ColS and others
olR isolates). An attempt to cure the infection with drug
ombinations including non-usual antimicrobial agents used
o treat A. baumannii infections, such as rifampin + colistin,
zithromycin + colistin, and chloramphenicol + colistin was
nsuccessful, leaving phage therapy as one of the few alterna-
ives for treating the patient. Five phages were detected withPlease cite this article in press as: Martins WM, et al. Clinical utilization
resistance in Brazil. Braz J Infect Dis. 2020. https://doi.org/10.1016/j.bjid.20
ctivity against the isolate recovered from this patient. The
hage was administered intravenously after 12 days of hos-
italization. It is not clear how many  different phages wereused in the cocktail, but an improvement in his health con-
dition was noted. Twelve days thereafter the patient was only
treated with phages because colistin was suspended on day 13
due to kidney injury. The patient received eight days of phage
therapy. However, before administration of the second phage
cocktail, his family opted to withdraw treatment and phage
therapy was discontinued on day 19, and the patient died on
day 20. Nevertheless, it is interesting to note that while the
phages were being administered the patient’s health condition
was maintained with some clinical improvement.25
Pseudomonas  aeruginosa
Although P. aeruginosa infections were treated with bacterio-
phages more  than 50 years ago,26 this therapy has recently
reemerged as an attractive alternative treatment.27 P. aerugi-
nosa is an opportunist pathogen, historically associated with
severe nosocomial infections and with a strong link with
cystic fibrosis and burn infections. It often displays an MDR
phenotype and numerous studies involving phages against
P. aeruginosa have been reported.27,28 Besides the capacity to
accumulate distinct resistance mechanisms, this microorgan-
ism is also able to produce a high level of biofilm, especially
on inanimate surfaces. Therefore, phages active against the
biofilm and the planktonic cultures are also important for
treating P. aeruginosa infections.28
Ten years ago, a clinical trial involving bacteriophage ther-
apy for P. aeruginosa infections was published demonstrating
that bacteriophage therapy against P. aeruginosa infections of bacteriophages: a new perspective to combat the antimicrobial
20.04.010
was safe and clinically effective. Twenty-four patients with
external otitis caused by P. aeruginosa strains were divided
into two (n = 12 each) treatment groups. Group 1 was treated
with a cocktail containing six phages with activity against P.
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aeruginosa (105 PFU of each phage diluted in a solution) while
the group 2 was treated with placebo. To be part of the study,
the patients’ bacteria were submitted to microbiological tests
to check if they were susceptible to at least to one phage con-
tained on the cocktail. The phage therapy was effective in
combating the infection and improving the ear health of the
patients. In addition, it was possible to detect how long the
phages remained in the region where the solution had been
applied. According to the authors, when the target bacterial
is reduced or completely eliminated, the phage replication
ceases leading to phage elimination. No signal of toxicity or
collateral effects were reported in this study, highlighting the
safety of this phage therapy.29
In Europe, a platform named PhageBurn represents one
of the biggest research studies in the phage field against
P. aeruginosa and Escherichia coli from burn infections, and
involved countries such as Belgium, France, and Switzerland
(http://www.phagoburn.eu). Recently, a double-blind random-
ized controlled trial was published using phages against P.
aeruginosa responsible for burn infections. In this study two
groups of patients either received a phage cocktail (n = 12/13)
containing 12 phages active against P. aeruginosa isolates, or
a traditional treatment (n = 13) using a standard of care for
patients with burn infections (1% sulfadiazine silver emul-
sion cream). The phage therapy was given to patients through
a topical cream containing the phages. Unfortunately, some
unexpected events compromised the study, and the trial was
stopped one year and a half after its beginning. After the
cream was manufactured, the phage concentration decreased
from 1 × 106 PFU to 1 × 102 PFU, (less than initially expected).
This resulted in inefficacy of PP1131 (a phage cocktail) due
to the extensive time taken to decrease the bacterial density
on the wound infection. However, it is important to notice
that although a lower phage concentration was used, the bac-
terial burden in burn wounds was decreased, showing that
phages were in fact active, but inferior to the standard of care
treatment.30
Klebsiella  pneumoniae
Several studies have focused or suggested alternatives to the
treatment of infections caused by K. pneumoniae.12,31 Thus,
several different types of phages have been discovered in the
last few years. Although it represents an important advance
in the field, the number of clinical trials using phages against
K. pneumoniae clones are insufficient to determine whether
phage therapy is a viable option for treating Klebsiella infec-
tions in humans.32–34
Recently, Corbellino et al.35 demonstrated the utilization
of a custom-made bacteriophage lytic preparation to gut
decolonization of a patient colonized by KPC-3-producing K.
pneumoniae. A 57-year old patient diagnosed with Crohn’s
disease had multiple sites of colonization by an MDR K.
pneumoniae belonging to ST307. The isolate was suscepti-
ble to ceftazidime-avibactam, which was successfully withPlease cite this article in press as: Martins WM, et al. Clinical utilization
resistance in Brazil. Braz J Infect Dis. 2020. https://doi.org/10.1016/j.bjid.20
reversion of all infection signs, but with later remission. Prob-
ably, the repeated cases of infections (UTI and BSI) by the
same pathogen could be attributed to the patient coloniza-
tion, evidenced by swab cultures. Five isolates recovered from 0;x x x(x x):xxx–xxx
the patient were sent to Georgi Eliava Institute of Bacterio-
phages in Tbilisi, Georgia for custom of phage preparation.
Interestingly, after three weeks of phage use by oral and
intra-rectal routes and no adverse effects, the patient did had
no urine, blood, or swab positive cultures with carbapenem-
resistance. Almost one year after the phage utilization, the
patient had other cases of BSI and UTI by K. pneumo-
niae; however, the recovered isolates belonged to other STs
(ST1109 and ST247), susceptible to most antimicrobial agents,
and not related to the KPC-3-producing K. pneumoniae only
susceptible to ceftazidime-avibactam frequently detected
before.35
Kumari et al.36 compared phage therapy and its respec-
tive protection in a wound burn model. For that study,
three groups of mice were created: the first consisted
of untreated animals, the second were treated with a
hydrogel containing the phages against a K. pneumoniae iso-
late, while the third group was treated with gentamicin
plus silver nitrate. The results demonstrated that a sin-
gle dose of phages resulted in decreased mortality of the
group treated with phages when compared with the other
groups.
Role  of  phages  in  infection  control:  a  good  way
to combat  MDR  pathogens
Phages are recognized as useful tools to combat infections
caused by many  types of microorganisms, including MDR-
pathogens.16 Some studies have also used phages on hand
sanitizer solution aiming to improve hand hygiene and avoid
the spread of MDR pathogens.37 Other authors have demon-
strated the capacity of decolonization of specific isolates by
phage action.38,39 Chhiber et al.39 have demonstrated that
phages in association with muropirocin were able to effec-
tively eradicate the colonizing MRSA population from the
nares of BALB/c mice. More  importantly, administration of
phage MR-10 combined with muropirocin reduced the fre-
quency of emergence of spontaneous muropirocin resistant
isolates at negligible levels. In addition, phages also could
be used for effective removal of hospital pathogens from
hard surfaces at hospital settings, especially when used in
combination with detergents.40 In a two-phase prospective
intervention study performed in Taiwan, the use of an aerosol
formulation containing bacteriophage in the ICU led to an
important reduction of new acquisition carbapenem resis-
tant A. baumanii infection from 8.57 per 1000 patients-day to
5.11 per 1000 patients-day (p = 0.0029). Moreover, a decrease in
carbapenem-resistance was observed (87.76% to 46.07%) in the
ICUs.41 These actions could reduce the number of infections
and, indirectly, reduce antibiotic usage for treating severe
infections.41
It is well known that the use of large amounts of antimi-
crobial agents is responsible for the selection of resistance
clones, contributing to high rates of antimicrobial resistance
that are frequently reported in Brazil.3 Another advantage that of bacteriophages: a new perspective to combat the antimicrobial
20.04.010
supports phage utilization in developing countries is the low
cost associated with phage isolation and administration.14
The process of discovery and production of a new antimi-
crobial agent is expensive in terms of time and resources.
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n contrast, phages could be easily identified in water envi-
onments, especially in sewage, through a simple process of
solation and purification.14 In Belgium, for instance, phages
an be used as a magistral formula, manipulated by a phar-
acist, following a series of criteria which determine the
hage safety.42,43 Regarding administration, while repeated
oses of antibiotics need to be administrated periodically to
chieve the pharmacokinetic and pharmacodynamic param-
ters, small doses of phages are enough since the number
f viral particles will expand after the cell infection.20 In
ountries with high social inequalities and limited resources
o invest in public health, low cost and effective alterna-
ives could be essential to tackle the high rates of deaths
aused every year by MDR-pathogens in nosocomial environ-
ents.
In addition, phages could be used in combination with
ntimicrobial agents increasing therapeutic efficacy and
ecreasing antimicrobial resistance development during
herapy.44,45 Another important advantage related to phage
tilization is the capacity to restore antimicrobial sensitivity.46
 study performed with a phage named OMKO1 revealed
he ability of this phage to interact with the outer mem-
rane proteins of MexAB and MexXY efflux systems in P.
eruginosa isolates. In a strategy to survive viral attack, the
ell seems to develop a mechanism by which several muta-
ions in the outer membrane proteins are selected during
acteria passage, decreasing virus-bacteria binding. However,
his modification on the outer membrane protein sequence
ecreased the capacity of bacteria to extrude the antibiotics,Please cite this article in press as: Martins WM, et al. Clinical utilization
resistance in Brazil. Braz J Infect Dis. 2020. https://doi.org/10.1016/j.bjid.20
ausing a drop in the MICs.46
ig. 2 – Timeline of the main events related to phage’s research d
vents related to phage research, while in the bottom, the main r
nvolving phages in Brazil were  obtained through research in the
r “Phages AND Brazil”. For a better understanding or to request
gure, we  suggest reading Salmond and Fineran.14 Additionally,
razil, we  suggest reading Almeida and Sundberg.47;x  x x(x x):xxx–xxx 5
Brazilian  studies  using  phages
Unfortunately, few phage studies have been reported in Brazil.
We strongly believe that research in this field is currently
under development in Brazil. However, to the best of our
knowledge, no clinical studies have been published. Interest-
ingly, a recently published historical review pointed Brazil as
one the pioneers of clinical phage utilization against S. aureus
and diarrheal bacilli even in the 1920 decade.47 However, after
the introduction of antimicrobial agents, and mainly due to
discontinuation of research in this field, investigations with
bacteriophages were practically abandoned in Brazil.47 Old
reports reiterate the Brazilian capacity to invest in bacterio-
phage technology, aiming at combating bacterial infections.
The resumption of studies related to phages in Brazil was
started in the last decade and these investigations are related
to different fields such as environmental research, veterinary
application, human health, and others, though legging behind
in terms of type of phages study conducted worldwide (Fig. 2).
Although more  related with contamination of aquatic envi-
ronment, a well-conducted study about somatic coliphages
was carried out in the coastal regions of São Paulo. In this
study, it was possible to identify and characterize different
types of phages against E. coli isolates. Interestingly, the pres-
ence of somatic coliphages is a well-established indication of
48 of bacteriophages: a new perspective to combat the antimicrobial
20.04.010
cess by researchers of Embrapa in Santa Catarina, Brazil.49
uring the last decades. At the top of the figure, world
esearches that were  conducted in Brazil. The investigations
 PubMed, using the indicators “Bacteriophages AND Brazil”
 more  information about events shown on the top of the
 for more  information about the early studies carried out in
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Similar results were observed almost 10 years later by Hun-
garo et al.,50 who showed the efficacy of phage utilization in
reducing Salmonella spp. isolates from chicken skin. Recently,
use of phages against P. aeruginosa in the poultry industry was
also evidenced in Minas Gerais State.51
A study involving clinical isolates, conducted in São Paulo,
detected the presence of phages against clinical isolates of P.
aeruginosa. Surprisingly, the phages were isolated from a col-
lection of P. aeruginosa isolates recovered from clinical samples
of different hospitals. Some phages showed activity against P.
aeruginosa MDR  and mucoid isolates. Although a clinical rela-
tion had been observed, no data about the clinical utilization
of these phages have been reported.52
Recently, a phage with activity against P. aeruginosa was
detected in the sewage from Tietê river in São Paulo city. This
phage, named BrSP1, was microbiologically and genomically
characterized and had its activity tested against P. aeruginosa
isolates from domestic animals. BrSP1 phage belonged to the
Caudovirales order, a genome with 66,189 bp, and had activity
against 51.4% of tested isolates. This fact highlights the possi-
bility of phage utilization in human and veterinary medicine.53
Limitation  of  bacteriophages  use  in  human
health  and  the  environment
Like all treatment options, phage utilization also presents lim-
itations that should be considered before clinical use. The
absence of large randomized clinical trials, safety evaluation
of phage therapy, and the numerous steps necessary before
clinical utilization of an identified phage are often reported
as the main limitations of this type of therapy. Furthermore,
little is known about the role of these bacteriophages in the
environment and their capacity to carry resistance genes. To
a better understanding of the limitations of phage treatment,
we recommend reading Principi et al.54
Conclusions
We  have provided evidence that use of phage therapy could be
a new way to combat MDR-pathogens and that this approach
would be useful in Brazil where the rates of antibiotic resis-
tance are on the rise. Currently, Brazil is going through an
economic crisis, a moment that always requires inexpensive
alternatives to tackle different national challenges. In this
case, lytic phage utilization could be one of these alternatives,
since these agents are simple, inexpensive and abundant in
different environments. In addition, more  studies need to be
supported in this field, aiming to reduce all uncertainties con-
cerning this type of therapy, to gain a new tool in the fight
against antimicrobial resistance in Brazil.
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